Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. H...owever, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.
TY - JOUR
AU - Todorović, Zoran
AU - Džoljić, Eleonora
AU - Novaković, Ivana
AU - Mirković, Duško
AU - Stojanović, Radan
AU - Nesić, Zorica
AU - Krajinović, Maja
AU - Prostran, Milica
AU - Kostić, Vladimir
PY - 2006
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/666
AB - Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.
PB - Elsevier Science BV, Amsterdam
T2 - Journal of the Neurological Sciences
T1 - Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy
VL - 248
IS - 1-2
SP - 56
EP - 61
DO - 10.1016/j.jns.2006.05.040
ER -
@article{
author = "Todorović, Zoran and Džoljić, Eleonora and Novaković, Ivana and Mirković, Duško and Stojanović, Radan and Nesić, Zorica and Krajinović, Maja and Prostran, Milica and Kostić, Vladimir",
year = "2006",
abstract = "Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Journal of the Neurological Sciences",
title = "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy",
volume = "248",
number = "1-2",
pages = "56-61",
doi = "10.1016/j.jns.2006.05.040"
}
Todorović, Z., Džoljić, E., Novaković, I., Mirković, D., Stojanović, R., Nesić, Z., Krajinović, M., Prostran, M.,& Kostić, V.. (2006). Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences
Elsevier Science BV, Amsterdam., 248(1-2), 56-61.
https://doi.org/10.1016/j.jns.2006.05.040
Todorović Z, Džoljić E, Novaković I, Mirković D, Stojanović R, Nesić Z, Krajinović M, Prostran M, Kostić V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences. 2006;248(1-2):56-61.
doi:10.1016/j.jns.2006.05.040 .
Todorović, Zoran, Džoljić, Eleonora, Novaković, Ivana, Mirković, Duško, Stojanović, Radan, Nesić, Zorica, Krajinović, Maja, Prostran, Milica, Kostić, Vladimir, "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy" in Journal of the Neurological Sciences, 248, no. 1-2 (2006):56-61,
https://doi.org/10.1016/j.jns.2006.05.040 . .
